Characterization of the specificity of peptide binding to four DR haplotypes - PubMed (original) (raw)
. 1990 Sep 15;145(6):1799-808.
Affiliations
- PMID: 2167910
Characterization of the specificity of peptide binding to four DR haplotypes
D O'Sullivan et al. J Immunol. 1990.
Abstract
This study describes the establishment of a peptide-binding assay for purified, detergent-solubilized DR molecules. For each of the DR specificities and peptides studied, a unique pattern of interaction was observed. Excellent correlation was detected between the DR1-, 2-, 5-, and 52a-binding capacities and the known DR restrictions of a panel of synthetic peptides. This supports the immunologic relevance of the binding assay, and emphasizes the importance of determinant selection in defining the immune response of individuals. We have also examined the capacity of a panel of DR-restricted peptides to compete with one another for binding to DR1. The results obtained are compatible with a single peptide-binding site on DR molecules. The peptide-binding capacity of the four different DR types (DR1, DR2, DR5, and DR52a) has been further examined by testing a collection of 133 different peptides. This collection is unbiased with respect to previously known DR binding and restrictions, and includes peptides of eukaryotic, bacterial, and viral origins. It was found that: 1) approximately 15 to 35% of the peptides tested bound any given DR type; 2) DR-binding capacities appeared to correlate with each other, suggesting that different alleles of the DR isotype may recognize related structures on an Ag molecule; and 3) despite the statistical correlation between binding capacity of different DR types, approximately 50% of the peptides that were positive binders still were specific in that they could bind only one of the four DR molecules tested. Degenerate binding (i.e., binding to most or all the DR molecules tested) was detected in only a minority of the cases analyzed (approximately 25%).
Similar articles
- Random association between the peptide repertoire of A2.1 class I and several different DR class II molecules.
Sette A, Vitiello A, Farness P, Furze J, Sidney J, Claverie JM, Grey HM, Chesnut R. Sette A, et al. J Immunol. 1991 Dec 1;147(11):3893-900. J Immunol. 1991. PMID: 1658152 - Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding.
Busch R, Hill CM, Hayball JD, Lamb JR, Rothbard JB. Busch R, et al. J Immunol. 1991 Aug 15;147(4):1292-8. J Immunol. 1991. PMID: 1869824 - On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs.
O'Sullivan D, Arrhenius T, Sidney J, Del Guercio MF, Albertson M, Wall M, Oseroff C, Southwood S, Colón SM, Gaeta FC, et al. O'Sullivan D, et al. J Immunol. 1991 Oct 15;147(8):2663-9. J Immunol. 1991. PMID: 1717570 - A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X, Bavari S, Ulrich R, Sadegh-Nasseri S, Ferrone S, McHugh L, Mage M. Zhu X, et al. Eur J Immunol. 1997 Aug;27(8):1933-41. doi: 10.1002/eji.1830270817. Eur J Immunol. 1997. PMID: 9295029 - Truncation analysis of several DR binding epitopes.
O'Sullivan D, Sidney J, Del Guercio MF, Colón SM, Sette A. O'Sullivan D, et al. J Immunol. 1991 Feb 15;146(4):1240-6. J Immunol. 1991. PMID: 1704034
Cited by
- Epitope prediction and identification- adaptive T cell responses in humans.
Sidney J, Peters B, Sette A. Sidney J, et al. Semin Immunol. 2020 Aug;50:101418. doi: 10.1016/j.smim.2020.101418. Epub 2020 Oct 31. Semin Immunol. 2020. PMID: 33131981 Free PMC article. Review. - The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides.
Schultz HS, Østergaard S, Sidney J, Lamberth K, Sette A. Schultz HS, et al. PLoS One. 2018 May 14;13(5):e0197407. doi: 10.1371/journal.pone.0197407. eCollection 2018. PLoS One. 2018. PMID: 29758051 Free PMC article. - Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires.
Scholz EM, Marcilla M, Daura X, Arribas-Layton D, James EA, Alvarez I. Scholz EM, et al. Front Immunol. 2017 Aug 21;8:984. doi: 10.3389/fimmu.2017.00984. eCollection 2017. Front Immunol. 2017. PMID: 28871256 Free PMC article. - The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.
Laubreton D, Bay S, Sedlik C, Artaud C, Ganneau C, Dériaud E, Viel S, Puaux AL, Amigorena S, Gérard C, Lo-Man R, Leclerc C. Laubreton D, et al. Cancer Immunol Immunother. 2016 Mar;65(3):315-25. doi: 10.1007/s00262-016-1802-0. Epub 2016 Feb 4. Cancer Immunol Immunother. 2016. PMID: 26847142 Free PMC article. - A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population.
McKinney DM, Southwood S, Hinz D, Oseroff C, Arlehamn CS, Schulten V, Taplitz R, Broide D, Hanekom WA, Scriba TJ, Wood R, Alam R, Peters B, Sidney J, Sette A. McKinney DM, et al. Immunogenetics. 2013 May;65(5):357-70. doi: 10.1007/s00251-013-0684-y. Epub 2013 Feb 8. Immunogenetics. 2013. PMID: 23392739 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources